ARA-290

Potential Benefits of ARA-290 Peptide

• Neuropathic Symptom Relief: Research suggests ARA 290 has shown promising results in alleviating neuropathic symptoms in patients with type 2 diabetes and sarcoidosis. Both intravenous and subcutaneous administration of this treatment have demonstrated its versatility as a therapeutic agent. [1] [2].
• Metabolic Control: Besides neuropathic symptom relief, ARA 290 also exhibits promising effects on metabolic control in subjects with type 2 diabetes [1]. This dual-action nature may make it an attractive therapeutic option for managing complex, co-morbid conditions.
• Increase in Corneal Nerve Fiber Density: A study demonstrated that ARA 290 can increase corneal nerve fiber density in patients with sarcoidosis-associated small nerve fiber loss [3]. This suggests that ARA 290 has regenerative properties, possibly due to its action on the innate repair receptor.
• Chronic Neuropathic Pain Treatment: ARA 290 acts at the innate repair receptor, a heteromer of the erythropoietin receptor and β-common receptor. This mechanism of action has been associated with the alleviation of chronic neuropathic pain in sarcoidosis patients [4].
• Promising SPECT Tracer for Cardiac Ischemia: ARA-290 peptide has been evaluated for its potential as a Single Photon Emission Computed Tomography (SPECT) tracer for targeting cardiac ischemic regions. The results suggest potential diagnostic benefits [5].
• Treatment of Painful Diabetic Neuropathy: Clinical trials have shown the safety and efficacy of ARA 290 in treating painful diabetic neuropathy [6]. Further larger clinical trials are needed for more conclusive results.
• Potential Neuroprotective Benefits: Apart from its analgesic properties, ARA 290 also appears to have neuroprotective benefits, making it a potential treatment for post-stroke depression [6].
• Attenuating Apoptosis and Inflammation: ARA 290 has been studied for its role in attenuating apoptosis and inflammation in critical limb ischemia, suggesting its potential use in vascular diseases [7] [8].
• Protection against Cytokine-Induced Apoptosis: Research has indicated that ARA 290 can protect rat islets from cytokine-induced apoptosis [8], suggesting possible applications in autoimmune conditions.
• Reducing Tissue Damage: Studies imply that ARA-290 peptide may reduce tissue damage by reducing inflammation [9].

References

[1] https://pubmed.ncbi.nlm.nih.gov/25387363/

[2] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3563705/

[3] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3883966/

[4] https://www.tandfonline.com/doi/ full/10.1517/21678707.2013.719289

[5] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC8917853/

[6] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC4365069/

[7] https://www.sciencedirect.com/science/ article/pii/S074152141301238X

[8] https://www.researchgate.net/ publication/310146980

[9] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC5741312/

ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://m.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.